D228 is an orally active antiinflammatory agent. D228 reduces ConA induced T lymphocyte cell proliferation (IC50: 42.85 µM) and LPS induced B lymphocyte cell proliferation (IC50: 3.15 µM). D228 is effective against inflammatory bowel disease (IBD). D228 alleviates the DSS (HY-116282C)-induced inflammation response in the IBD model by downregulating the MyD88/TRAF6/p38 signaling[1].
Molekulargewicht:
484.45
Reinheit:
99.77
CAS Nummer:
[2676188-98-8]
Formel:
C22H28O12
Target-Kategorie:
MyD88,p38 MAPK
Anwendungsbeschreibung:
MCE Product type: Reference compound
* Mehrwertsteuer und Versandkosten nicht enthalten. Irrtümer und Preisänderungen vorbehalten
